CN117427149A - 护眼组合物、含该护眼组合物的产品、制备方法和应用 - Google Patents
护眼组合物、含该护眼组合物的产品、制备方法和应用 Download PDFInfo
- Publication number
- CN117427149A CN117427149A CN202210834025.6A CN202210834025A CN117427149A CN 117427149 A CN117427149 A CN 117427149A CN 202210834025 A CN202210834025 A CN 202210834025A CN 117427149 A CN117427149 A CN 117427149A
- Authority
- CN
- China
- Prior art keywords
- eye
- parts
- protecting
- percent
- eye protection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- FDHNLHLOJLLXDH-JIYHLSBYSA-N (e)-3-(3-hydroxy-4-methoxyphenyl)-1-[2-hydroxy-6-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]prop-2-en-1-one Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C(=O)C(C(=C1)OC)=C(O)C=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 FDHNLHLOJLLXDH-JIYHLSBYSA-N 0.000 claims abstract description 31
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 31
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 31
- 229940076640 hesperidin methylchalcone Drugs 0.000 claims abstract description 31
- 229960005375 lutein Drugs 0.000 claims abstract description 31
- 235000012680 lutein Nutrition 0.000 claims abstract description 31
- 239000001656 lutein Substances 0.000 claims abstract description 31
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 31
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 31
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 31
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 31
- 102000008186 Collagen Human genes 0.000 claims abstract description 30
- 108010035532 Collagen Proteins 0.000 claims abstract description 30
- 229920001436 collagen Polymers 0.000 claims abstract description 30
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 29
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 29
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 29
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 29
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 29
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229940116229 borneol Drugs 0.000 claims abstract description 29
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 29
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 29
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims abstract description 29
- 229920000669 heparin Polymers 0.000 claims abstract description 29
- 229960001008 heparin sodium Drugs 0.000 claims abstract description 29
- 229940041616 menthol Drugs 0.000 claims abstract description 29
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 claims abstract description 28
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 claims abstract description 27
- 229940090813 madecassoside Drugs 0.000 claims abstract description 27
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 11
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 11
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 11
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 11
- 229960005188 collagen Drugs 0.000 claims abstract description 8
- 239000004094 surface-active agent Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 18
- 229930003270 Vitamin B Natural products 0.000 claims description 17
- 235000019156 vitamin B Nutrition 0.000 claims description 17
- 239000011720 vitamin B Substances 0.000 claims description 17
- 150000001298 alcohols Chemical class 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- -1 hydroxy asiaticoside Chemical compound 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 208000006550 Mydriasis Diseases 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229940022757 asiaticoside Drugs 0.000 claims description 2
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- 229940116406 poloxamer 184 Drugs 0.000 claims description 2
- 229920001992 poloxamer 407 Polymers 0.000 claims description 2
- 229940044476 poloxamer 407 Drugs 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims 1
- 210000001508 eye Anatomy 0.000 abstract description 124
- 230000028327 secretion Effects 0.000 abstract description 30
- 229940001447 lactate Drugs 0.000 abstract description 27
- 210000004561 lacrimal apparatus Anatomy 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 210000005036 nerve Anatomy 0.000 abstract description 5
- 230000004488 tear evaporation Effects 0.000 abstract description 5
- 208000005494 xerophthalmia Diseases 0.000 abstract description 5
- 238000005728 strengthening Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 62
- 229920002385 Sodium hyaluronate Polymers 0.000 description 24
- 229940010747 sodium hyaluronate Drugs 0.000 description 24
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 23
- 238000000034 method Methods 0.000 description 13
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 12
- 206010013774 Dry eye Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 7
- 208000003464 asthenopia Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000607 artificial tear Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229940108690 glucosyl hesperidin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical group CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种护眼组合物、含该护眼组合物的产品、制备方法和应用。所述护眼组合物含薄荷醇乳酸酯、冰片、乙酰半胱氨酸、维生素B12、橙皮苷甲基查尔酮、叶黄素、羟基积雪草甙、肝素钠和胶原;所述护眼产品,其包含护眼组合物。本发明的护眼组合物及产品可适用于干眼症患者,使用时结合眼周穴位,可以促使有效成分更好的吸收,引起泪腺神经兴奋,加强泪腺主动分泌功能,从而促进泪液分泌,缓解了眼部疲劳和泪液蒸发过快的问题;同时,对皮肤无刺激,具有清凉感,极大的提高了人群的接受度。另外,使用时无需闭眼,更方便快捷,且不受场地和仪器限制。
Description
技术领域
本发明属于医疗保健技术领域,具体涉及一种护眼组合物、含该护眼组合物的产品、制备方法和应用。
背景技术
随着人们居住环境、生活方式、工作强度等的改变以及电子设备的普及,干眼症的发病率逐年升高,已成为最常见的眼部疾病之一,我国干眼症的发病率已达21-30%,且干眼症的治疗需求也逐年增加。干眼症已经成为全球流行性疾病之一,且干眼症的患病人群现已逐渐呈现年轻化的趋势。近年来,对干眼症发病机制的研究已不再局限于泪液分泌不足和泪液蒸发增加,而是涉及泪膜稳定性、泪液渗透压、神经感觉异常及眼表炎症等多方面。
干眼作为一种慢性病,目前无特效疗法,需要患者维持长期治疗。目前眼科临床多采用人工泪液的治疗方法进行干预缓解症状为主,泪液成分的替代治疗,使用人工泪液或自体血清,增加眼部的湿润度,减轻眼部干涩等症状,但是人工泪液的疗效只是暂时的,只能暂时改善干眼症状,不能从根本上增加泪液的分泌,且添加防腐剂的人工泪液长期滴注也会对眼睛有一定损害。
传统物理治疗方法如熏蒸、雾化、眼周按摩、热敷、湿房镜,这些物理治疗方法周期长,往往需要持续性的坚持周期治疗,且在治疗过程中全程闭眼,治疗周期长,消费者无法坚持使用,对于干眼病一族来说并不是首选。
发明内容
为了解决上述技术问题,本发明提供了一种护眼组合物、含该护眼组合物的产品、制备方法和应用。本发明的护眼组合物在使用时结合眼周穴位,能够更好的被人体吸收,通过引起泪腺神经兴奋,加强泪腺主动分泌功能,从而促进泪液分泌,实现缓解眼部疲劳的功效。同时,本发明的护眼产品使用时无需闭眼,更方便快捷,使用不受场地和仪器限制。
为了实现上述目的,本发明采用以下的技术方案:
本发明提供了一种护眼组合物,包括薄荷醇乳酸酯、冰片、乙酰半胱氨酸、维生素B12、橙皮苷甲基查尔酮、叶黄素、羟基积雪草甙、肝素钠和胶原。
其中,乙酰半胱氨酸对胶原酶有100%抑制效果,是治疗溃疡性角膜疾病最理想的药物,能够提高细胞呼吸及组织营养,促进角膜上皮再生,改善眼部新陈代谢,延缓眼部细胞老化,具有减少眼部疲劳及抗衰老之功效;维生素B12可以增加眼部对氧利用率,促进眼部能量代谢及增加睫状体血流量来增强眼部的调解能力;橙皮苷甲基查尔酮可以增强毛细血管抵抗力,使毛细血管渗透正常,促进血液循环;叶黄素是构成人眼视网膜黄斑区域的主要色素,可以保护视力;羟基积雪草甙具有抗氧化、抗菌、调节免疫等功能;肝素钠可以增加皮肤的血管通透性,改善局部血管循环,促进皮肤营养的供给和代谢废物的排泄,对皮肤起到良好的保健和养护作用;胶原可以使皮肤中的胶原蛋白活性增加,保持角质层水分以及纤维结构的完整性,改善皮肤细胞生存环境和促进皮肤组织的新陈代谢,增强循环;薄荷醇乳酸酯和冰片,带来清凉感可有效降低皮肤局部温度,达到使人放松的效果。
本发明的护眼组合物以薄荷醇乳酸酯、冰片、乙酰半胱氨酸、维生素B12、橙皮苷甲基查尔酮、叶黄素、羟基积雪草甙、肝素钠和胶原为主要成分,可适用于干眼症患者,不仅具有改善泪液分泌情况,还可以缓解眼部疲劳和泪液蒸发过快的问题;同时,对皮肤无刺激,具有清凉感,极大的提高了人群的接受度。
在一些优选的技术方案中,所述护眼组合物,包含以下重量份的组分:薄荷醇乳酸酯0.5-2份、冰片0.5-3份、乙酰半胱氨酸0.1-1份、维生素B12 0.2-2份、橙皮苷甲基查尔酮0.5-3份、叶黄素0.01-1.2份、羟基积雪草甙0.2-2份、肝素钠0.05-0.2份和胶原0.1-5份。
本发明还提供了上述护眼组合物在制备护眼产品中的应用。
本发明的护眼产品在使用时结合眼周穴位,一方面可以促使有效成分更好的吸收,通过引起泪腺神经兴奋,加强泪腺主动分泌功能,从而促进泪液分泌,实现缓解眼部疲劳的功效;另一方使用时无需闭眼,更方便快捷,且不受场地和仪器限制。
本发明还提供了一种护眼产品,包含上述的护眼组合物、醇类、表面活性剂和水。
其中,表面活性剂可以使护眼组合物中的薄荷醇乳酸酯和冰片充分溶于水,醇类为辅助乳化作用,使护眼组合物更加稳定不析出,透明质酸钠为骨架材料,且可减少对皮肤的刺激,安全性高。
在一些优选的实施例中,所述醇类为丁二醇、丙二醇、甘油和戊二醇中的至少一种。
在一些优选的实施例中,所述表面活性剂为聚山梨醇酯-20、氢化卵磷脂、卵磷脂、泊洛沙姆184和泊洛沙姆407中的至少一种。
在一些优选的实施例中,所述的护眼产品,按重量百分比计,含护眼组合物2-14%、醇类2-5%、表面活性剂0.1-1%和水余量。
本发明还提供了一种上述护眼产品的制备方法,包括以下步骤:
S1、将配方量的冰片、薄荷醇乳酸酯、醇类和表面活性剂混合均匀,加热溶解后,再加入水,搅拌,得到乳化液;
S2、向步骤S1得到的乳化液中加入配方量的乙酰半胱氨酸、维生素B12、橙皮苷甲基查尔酮、叶黄素、羟基积雪草甙、肝素钠和胶原,混合搅拌,即得所述护眼产品。
其中,步骤S1加热温度为55-65℃。
其中,步骤S2中乳化液温度降至40-48℃时,加入配方量的乙酰半胱氨酸、维生素B12、橙皮苷甲基查尔酮、叶黄素、羟基积雪草甙、肝素钠和胶原。
在一些优选的实施例中,本发明的护眼产品可以作为制剂原料,进一步制成具有护眼功效的化妆品。基于此,本发明还提供了上述护眼产品在制备具有护眼功效的化妆品中的应用。
所述的化妆品包括但不限于精华液、凝胶剂、贴片或面膜。
具体地,所述化妆品使用时涂抹或覆盖的穴位包含:承泣、四白和瞳子髎。为进一步强化效果,使用时承泣、四白和瞳子髎可用食指指腹加强点按,每次2-3秒,重复2-3次。
本发明还提供了一种由护眼产品制备的护眼贴片。
在一些优选的实施例中,本发明还提供了一种护眼微针贴片,按重量百分比计,由骨架材料5-35%和护眼产品余量制成。
优选地,所述骨架材料包括透明质酸钠、明胶、海藻糖、聚乙烯基吡咯烷酮、聚二乙醇、聚乳酸、聚乙烯醇、羟甲基纤维素、羟乙基纤维素、羟丙基甲基纤维素中的至少一种。
在一些优选地实施例中,所述护眼微针贴片的制备方法,包括以下步骤:
(1)将护眼产品均质,去除气泡,得到微针制作液;
(2)将步骤(1)制备的微针制作液灌注于模具中,成型、干燥和剥离,得到所述护眼微针贴片。
优选地,步骤(1)所述去除气泡的方法包括但不限于真空和/或离心。
优选地,步骤(2)所述灌注的方法包括但不限于高压喷洒、离心、真空吸附或自流平。
优选地,步骤(2)中所述护眼微针贴片,包括第一微针阵列区域和第二微针阵列区域,共800 1000个可溶性微针,可溶性微针呈圆锥形,针头长度为300μm,微针间距为600μm。第一微针阵列区域和第二微针阵列区域之间由无针连接区域连接。所述第一微针阵列区域可溶性微针覆盖承泣、四白二个穴位,第二微针阵列区域可溶性微针覆盖穴位瞳子髎。无针区域使微针贴片与脸部更加贴合。
本发明的有益效果为:
(1)本发明的护眼组合物以薄荷醇乳酸酯、冰片、乙酰半胱氨酸、维生素B12、橙皮苷甲基查尔酮、叶黄素、羟基积雪草甙、肝素钠和胶原为主要成分,可适用于干眼症患者,不仅可以改善泪液分泌,还可以缓解眼部疲劳和泪液蒸发过快的问题;同时,对皮肤无刺激,具有清凉感,极大的提高了人群的接受度。
(2)本发明的护眼产品在使用时结合眼周穴位,其中,承泣滋阴清热、调畅眼部气血;四白主治目疾;瞳子髎主治屈光不正、结膜炎,不仅可以更好地吸收,发挥快速护理作用,还可以引起泪腺神经兴奋加强泪腺主动分泌功能促进泪液分泌,具有舒缓眼部疲劳的功效。
(3)本发明制备的护眼产品使用更方便快捷,无需闭眼使用,使用不受场地和仪器限制,无需耗费大量时间去医院等专业机构进行治疗。
附图说明
图1为本发明护眼产品的使用示意图。
其中,1、穴位承泣,2、穴位四白,3、穴位瞳子髎。
具体实施方式
以下结合特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。
在进一步描述本发明具体实施方式之前,应理解,本发明的保护范围不局限于下述特定的具体实施方案;还应当理解,本发明实施例中使用的术语是为了描述特定的具体实施方案,而不是为了限制本发明的保护范围。
本发明对所采用原料的来源不作限定,如无特殊说明,本发明所采用的原料均为本技术领域普通市售品。具体地,本实施例采用的醇类为丁二醇,所述表面活性剂为聚山梨醇酯-20,透明质酸钠为分子量30-50KDa的低分子透明质酸钠,冰片以松节油为主要原料合成的含量为99-100%的冰片,薄荷醇乳酸酯,购自广州佳德生物科技有限公司,羟基积雪草甙,购自广州玫芙生物科技有限公司或CAS为34540-22-2,乙酰半胱氨酸,购自湖北康宝泰精细化工有限公司,叶黄素,购自浦瑞生物医药有限公司,胶原,购自江苏创健医疗科技有限公司,肝素钠,购自广州欣浪生物化工有限公司,维生素B12,购自广州旭帆贸易有限公司,橙皮苷甲基查尔酮,购自广州旭帆贸易有限公司。
实施例1护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片0.5份、薄荷醇乳酸酯0.5份、乙酰半胱氨酸0.5份、维生素B12 2份、叶黄素0.15份、肝素钠0.1份、胶原0.2份、羟基积雪草甙0.2份和橙皮苷甲基查尔酮0.5份。
实施例2护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮1份。
实施例3护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片2份、薄荷醇乳酸酯1份、乙酰半胱氨酸1份、维生素B12 0.5份、叶黄素0.2份、肝素钠0.05份、胶原1份、羟基积雪草甙1.3份和橙皮苷甲基查尔酮0.8份。
实施例4护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片3份、薄荷醇乳酸酯2份、乙酰半胱氨酸1份、维生素B12 2份、叶黄素1.2份、肝素钠0.1份、胶原5份、羟基积雪草甙2份和橙皮苷甲基查尔酮3份。
实施例5护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1.75份、薄荷醇乳酸酯1.25份、乙酰半胱氨酸0.55份、维生素B12 1.1份、叶黄素0.6份、肝素钠0.07份、胶原2.5份、羟基积雪草甙1.3份和橙皮苷甲基查尔酮2份。
实施例6护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片0.5份、薄荷醇乳酸酯0.5份、乙酰半胱氨酸0.1份、维生素B12 0.2份、叶黄素0.01份、肝素钠0.05份、胶原0.1份、羟基积雪草甙0.6份和橙皮苷甲基查尔酮1份。
对比例1护眼产品
所述护眼产品,不含护眼组合物,按重量百分比计,醇类3%、表面活性剂0.5%、透明质酸钠21%和水75.5%。
对比例2护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸1.2份、维生素B12 1份、叶黄素0.01份、肝素钠0.04份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮0.4份。
对比例3护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和葡糖基橙皮苷1份。
对比例4护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.05份、维生素B12 1份、叶黄素1.4份、肝素钠0.25份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮3.2份。
对比例5护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水65.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯0份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮1份。
实施例7护眼产品
所述护眼产品,按重量百分比计,含护眼组合物2%、醇类3%、表面活性剂0.1%、透明质酸钠5%和水89.9%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮1份。
实施例8护眼产品
所述护眼产品,按重量百分比计,含护眼组合物6%、醇类4%、表面活性剂0.5%、透明质酸钠15%和水74.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮1份。
实施例9护眼产品
所述护眼产品,按重量百分比计,含护眼组合物10%、醇类2%、表面活性剂0.5%、透明质酸钠25%和水62.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮1份。
实施例10护眼产品
所述护眼产品,按重量百分比计,含护眼组合物14%、醇类5%、表面活性剂1%、透明质酸钠35%和水45%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮1份。
对比例6护眼产品
所述护眼产品,按重量百分比计,含护眼组合物1%、醇类3%、表面活性剂0.5%、透明质酸钠21%和水74.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮1份。
对比例7护眼产品
所述护眼产品,按重量百分比计,含护眼组合物8%、醇类3%、表面活性剂0.05%、透明质酸钠21%和水67.95%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮1份。
对比例8护眼产品
所述护眼产品,按重量百分比计,含护眼组合物16%、醇类3%、表面活性剂0.5%、透明质酸钠38%和水42.5%,
其中,所述护眼组合物,包括以下重量份的组分:冰片1份、薄荷醇乳酸酯2份、乙酰半胱氨酸0.1份、维生素B12 1份、叶黄素0.01份、肝素钠0.2份、胶原0.2份、羟基积雪草甙0.8份和橙皮苷甲基查尔酮1份。
实施例1-10和对比例1-8所述护眼产品,采用以下的方法制备而成,具体为:
(1)将配方量的冰片、薄荷醇乳酸酯、醇类和表面活性剂混合均匀,水浴加热至55-65℃至原料完全溶解透明,然后加入配方量的水,打开均质机充分乳化,得到乳化液;
(2)向步骤(1)得到的乳化液中,加入配方量的乙酰半胱氨酸、维生素B12、橙皮苷甲基查尔酮、叶黄素、羟基积雪草甙、肝素钠和胶原,搅拌混合,得到配置液;
(3)向步骤(2)得到的配置液中加入配方量的透明质酸钠,置于离心均质机中,混合均质即可。
将实施例1-10和对比例1-8制备的护眼产品,进一步加工制备成可溶性微针贴片,具体地,所述可溶性微针贴片的制备方法为:
(1)将护眼产品置于离心均质机中均质,去除气泡,得到均一且无气泡的微针制作液;
其中,步骤(1)中所述去除气泡的方法包括但不限于真空和/或离心。
(2)将步骤(1)制备的微针制作液灌注于模具中,成型,干燥和剥离,即得;
其中,步骤(2)中所述灌注的方法包括但不限于高压喷洒、离心、真空吸附或自流平;所述剥离后还可以根据剥离得到的微针片的情况进行裁切,将剥离后的微针片裁切到预定大小和形状。
制备得到的可溶性微针贴片,包括第一微针阵列区域和第二微针阵列区域,共8001000个可溶性微针,其可溶性微针呈圆锥形,针头长度为300μm,微针间距为600μm,。第一微针阵列区域和第二微针阵列区域之间由无针连接区域连接。所述第一微针阵列区域可溶性微针覆盖承泣、四白二个穴位,第二微针阵列区域可溶性微针覆盖穴位瞳子髎。无针区域使微针贴片与脸部更加贴合。
一、护眼微针贴片功效评价
1、泪液分泌试验(SIT)
对实施例1-10及对比例1-8所得的可溶性护眼微针贴片进行泪液分泌效果测试。
(1)测试人群:选取180名具有干眼症的患者,进行随机分组,每组10人。
(2)测试区域:左眼。
(3)使用方法:隔天使用,每次使用时间90min,持续使用4周;微针贴片轻轻放眼周位置(如图1所述),施加力度垂直按压(用食指、中指、无名指,三指的指腹垂直用力按压,每次3-5秒,重复2-3次)以确保贴片与皮肤充分贴牢,重要穴位:承泣、四白和瞳子髎可用食指指腹加强点按,每次2-3秒,重复2-3次。
(4)测试方法:治疗前后各检查1次。将泪液检测滤纸条一端折叠5mm置于下睑外1,3结膜囊,闭合双眼5min,测量折叠处的湿润长度。
诊断标准:①主观症状:眼部有干涩感、疲倦感、异物感、眼红、视力减弱、烧灼样刺痛、怕光等症状两项以上;②泪膜破裂时间不超过5s;或(和)泪液分泌试验结果为分泌量不超过5mm(5min内);③角结膜荧光素染色试验阳性;泪膜破裂时间在5~10s;泪液分泌试验结果不超过10mm。同时具备①+②或①+③即可诊断干眼。
症状积分评定:按主症的严重程度将评分标准定为:①0分:正常;②2分:轻度;③4分:中度;④6分:重度。分别对干涩感、视物疲劳感、烧灼痛感、异物感进行主观评定,治疗前后各评分1次。
泪液分泌测试和主观感受评价结果分别如表1和2所示。
表1实施例及对比例的泪液分泌测试结果
组别 | 使用前泪液分泌量/mm | 使用4周后泪液分泌量/mm | 使用前后改善量/mm |
实施例1 | 3.1 | 7.6 | 4.5 |
实施例2 | 3.0 | 8.5 | 5.5 |
实施例3 | 2.8 | 7.1 | 4.3 |
实施例4 | 3.0 | 6.9 | 3.9 |
实施例5 | 2.9 | 6.3 | 3.2 |
实施例6 | 2.6 | 6.5 | 3.9 |
对比例1 | 3.0 | 3.2 | 0.2 |
对比例2 | 2.9 | 5.1 | 2.2 |
对比例3 | 2.8 | 5.4 | 2.6 |
对比例4 | 3.1 | 6.0 | 2.9 |
对比例5 | 3.3 | 5.8 | 2.5 |
实施例7 | 2.9 | 4.1 | 1.2 |
实施例8 | 2.5 | 4.7 | 2.2 |
实施例9 | 2.6 | 7.6 | 5.0 |
实施例10 | 3.1 | 8.3 | 5.2 |
对比例6 | 3.0 | 3.5 | 0.5 |
对比例7 | 2.9 | 5.3 | 2.3 |
对比例8 | 3.0 | 5.5 | 2.5 |
由上表1可知,本发明实施例1-6制备的可溶性微针贴片,其可以有效促进泪液分泌,缓解眼干症的不适感,而对比例1不含护眼组合物的可溶性微针贴片不能促进泪液分泌缓解不适感。表明,本发明的护眼组合物可以促进泪液分泌,具有护眼的效果。
同时,根据对比例2-4可知,当改变乙酰半胱氨酸、叶黄素、肝纳素和橙皮苷甲基查尔酮的用量不在本申请要求保护的范围内,或利用常规的葡糖基橙皮苷代替橙皮苷甲基查尔酮其制备的可溶性微针贴片促进泪液分泌的功效,相比实施例2显著下降,表明,在本发明要求保护的技术方案中,乙酰半胱氨酸、叶黄素、肝纳素和橙皮苷甲基查尔酮可以协同增效促进泪液分泌,产生了预料不到的技术效果。
同时,根据实施例7-10和对比例6-8可知,本发明的护眼产品,含护眼组合物、醇类、表面活性剂和透明质酸钠,其制备的可溶性微针贴片可以实现促进泪液分泌的功效,但当改变其组分的用量不在本发明要求保护的范围内时会对促进泪液分泌的功效产生一定影响。
表2主观感受评价结果
综上所述,本发明的护眼组合物及产品可适用于干眼症患者,使用时结合眼周穴位,可以促使有效成分更好的吸收,引起泪腺神经兴奋,加强泪腺主动分泌功能,从而促进泪液分泌,缓解了眼部疲劳和泪液蒸发过快的问题;同时,对皮肤无刺激,具有清凉感,极大的提高了人群的接受度。另外,使用时无需闭眼,更方便快捷,且不受场地和仪器限制。
需要强调的是,本发明所述的实施例是说明性的,而不是限定性的,因此本发明包括并不限于具体实施方式中所述的实施例,凡是由本领域技术人员根据本发明的技术方案得出的其他实施方式,同样属于本发明保护的范围。
Claims (10)
1.一种护眼组合物,其特征在于,包含以下重量份的组分:薄荷醇乳酸酯0.5-2份、冰片0.5-3份、乙酰半胱氨酸0.1-1份、维生素B12 0.2-2份、橙皮苷甲基查尔酮0.5-3份、叶黄素0.01-1.2份、羟基积雪草甙0.2-2份、肝素钠0.05-0.2份和胶原0.1-5份。
2.一种护眼产品,其特征在于,按重量百分比计,含权利要求1所述的护眼组合物2-14%、醇类2-5%、表面活性剂0.1-1%和水余量。
3.根据权利要求2所述的护眼产品,其特征在于,所述醇类为丁二醇、丙二醇、甘油和戊二醇中的至少一种。
4.根据权利要求2所述的护眼产品,其特征在于,所述表面活性剂为聚山梨醇酯-20、氢化卵磷脂、卵磷脂、泊洛沙姆184和泊洛沙姆407中的至少一种。
5.一种权利要求2-4任一项所述护眼产品的制备方法,其特征在于,包括以下步骤:
S1、将配方量的冰片、薄荷醇乳酸酯、醇类和表面活性剂混合均匀,加热溶解后,再加入水,搅拌,得到乳化液;
S2、向步骤S1得到的乳化液中加入配方量的乙酰半胱氨酸、维生素B12、橙皮苷甲基查尔酮、叶黄素、羟基积雪草甙、肝素钠和胶原,混合搅拌,得到护眼产品。
6.权利要求2-4任一项所述的护眼产品或权利要求5所述制备方法制备的护眼产品在制备具有护眼功效的化妆品中的应用。
7.根据权利要求6所述的应用,其特征在于,所述化妆品为精华液、凝胶剂、贴片或面膜。
8.根据权利要求6所述的应用,其特征在于,所述化妆品使用时涂抹或覆盖的穴位包含:承泣、四白和瞳子髎。
9.一种护眼贴片,其特征在于,由权利要求2-4任一项所述的护眼产品或权利要求5所述制备方法制备的护眼产品制成。
10.一种护眼微针贴片,其特征在于,按重量百分比计,由骨架材料5-35%和权利要求2-4任一项所述的护眼产品或权利要求5所述制备方法制备的护眼产品余量制成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210834025.6A CN117427149A (zh) | 2022-07-14 | 2022-07-14 | 护眼组合物、含该护眼组合物的产品、制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210834025.6A CN117427149A (zh) | 2022-07-14 | 2022-07-14 | 护眼组合物、含该护眼组合物的产品、制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117427149A true CN117427149A (zh) | 2024-01-23 |
Family
ID=89546825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210834025.6A Pending CN117427149A (zh) | 2022-07-14 | 2022-07-14 | 护眼组合物、含该护眼组合物的产品、制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117427149A (zh) |
-
2022
- 2022-07-14 CN CN202210834025.6A patent/CN117427149A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111544390B (zh) | 治疗睑板腺功能障碍和/或过敏性结膜炎的中药制剂及超声雾化和纳米喷雾制剂和制备方法 | |
EP3721890A1 (en) | Ophthalmic drug preparation and uses thereof | |
CN108125996A (zh) | 一种用于视疲劳、干眼的眼用制剂 | |
CN113133957A (zh) | 一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 | |
CN111773114A (zh) | 一种负离子水晶眼贴膜 | |
CN117427149A (zh) | 护眼组合物、含该护眼组合物的产品、制备方法和应用 | |
CN114632138A (zh) | 一种冷敷眼部凝胶液及其制备方法和制备的石墨烯冷敷眼贴 | |
CN113069373A (zh) | 一种干眼眼霜、制备方法及应用 | |
KR20120009183A (ko) | 인간 중간엽줄기세포의 분화 촉진용 조성물 | |
CA3143557A1 (en) | External use composition comprising paeonol and panthenol or pharmaceutically acceptable salts thereof as active ingredients | |
CN111110817A (zh) | 一种治疗眼疾的中药组合物、制备方法及其应用 | |
CN112915100A (zh) | 一种用于预防和治疗瘢痕的组合物 | |
CN105726698B (zh) | 一种缓解视疲劳的玫瑰组合物、眼贴及其制备方法 | |
CN111544468B (zh) | 一种眼部护理用洗眼液 | |
CN108498615A (zh) | 一种基于一氧化氮原理改善眼睛的中药眼保健贴及其制备方法 | |
CN114099551B (zh) | 缓解视疲劳润眼组合物 | |
RU2807377C1 (ru) | Способ проведения гирудотерапии для коррекции возрастных изменений кожи лица | |
KR20180117313A (ko) | 눈 다크 서클 제거용 눈 패치 | |
CN106491512A (zh) | 一种生物蛋白酶新生精华霜 | |
CN107582771A (zh) | 贴敷眼睑缓解视疲劳的贴敷制剂及其制备方法 | |
CN107638371A (zh) | 一种含有何首乌干细胞提取物的祛眼袋组合物及其应用 | |
CN106138930B (zh) | 一种含有中药有效成分治疗鱼鳞病的乳液及其制备方法 | |
CN112891401A (zh) | 一种缓解视疲劳的中药组合物及其制备方法 | |
CN113876882A (zh) | 一种治疗干眼的中药熏眼组合物和中药熏眼包与熏剂、雾化制剂或眼用喷雾剂及制备方法 | |
CN116077407A (zh) | 一种眼部保健按摩组合物、制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |